NEW DIASTEREOSELECTIVE SYNTHESIS OF NOVEL CHIRAL γ -(AMINOALKYL)- α -Hydroxy- γ -Lactones and their application for the synthesis of renin inhibitors


Rainer Metternich* and Werner Lüdi

Preclinical Research, SANDOZ Ltd., CH-4002 Basle, Switzerland

Summary: Using a new aldol approach, starting <u>directly</u> from the pyruvate enolate 7 and reacting it chelate controlled with the chiral α -aminoaldehyde 8, the aldol adduct 9 is obtained diastereoselectively and is converted subsequently by 1,3-induced asymmetric hydrogenation into the chiral title compound <u>11</u>. This novel lactone is further used for the synthesis of potent renin inhibitors.

Dipeptide isosteres, i.e. dipeptides in which the amide-CONH linkage has been replaced by some approximately isosteric functional group e.g. ketomethylene¹ or hydroxyethy-lene^{1,2a} resp. dihydroxyethylene^{2b} group, have been used to prepare transition state analogues as enzyme inhibitors.


In the course of our work on renin inhibitors,³ we were interested in compounds incorporating the 2-oxy-substituted hydroxyethylene dipeptide isostere 1:




Therefore we developed a new stereocontrolled synthesis of α -hydroxy- γ -lactones. Our synthetic strategy is shown in scheme 1. The required two new stereocentres should result by a sequence of chelate controlled⁴ 1,2-induced asymmetric aldol addition of a pyruvate enolate $\underline{4}$ to a chiral α -aminoaldehyde $\underline{5}$ and 1,3-induced asymmetric hydrogenation of the resulting α -enol- γ -lactone 3.

Previous syntheses of α -keto- γ -lactones resp. α -enol- γ -lactones⁵ by condensation of α -keto acids or esters with aldehydes followed by lactonization^{6,7} are often accompanied by side reactions.⁷ Hence, synthons of pyruvate enolate are used to circumvent this problem.⁸ Nevertheless, we felt that it should be worthwhile to examine the <u>direct</u> reaction of a lithiated methyl pyruvate with a N-lithiated chiral α -aminoaldehyde.

Starting from BOC-L-cyclohexylalaninal⁹ <u>8</u> and the pyruvate enolate <u>7</u>, the corresponding α -keto- γ -lactone (which exists exclusively in the enol form⁵ 9) was formed diastereo-




selectively (9:10=90:10) and was converted subsequently into the chiral α -hydroxy- γ -lactone 11 which was obtained as a white crystalline compound in 59% overall yield.




SCHEME 2

Conversion of <u>11</u> to the corresponding oxazolidinone <u>12</u> (1. $BuNH_2$, R.T.; 2. NaH, THF) permitted assignment of the relative configuration between C-4 and C-5 by ¹H-NMR arguments: ^{10,11}




The observed diastereoselectivity is not consistent with the Felkin model¹² for asymmetric induction. However, with regard to the fact that the enolate $\underline{7}$ adds to the chelated aldehyde species A, this result is consistent with the cyclic Cram model⁴ in which the incoming nucleophile adds from the less hindered side of the chelate (kinetically favoured pathway a). One might also propose equilibration of the two chelated species B and C via a retroreaction to species A.¹³ The <u>trans</u> isomer B is then thermodynamically favoured over the more hindered <u>cis</u> isomer C (scheme 3):



Typical aldol-hydrogenation procedure

To a solution of 63 mmol of LDA in THF/hexane (1.5 mol⁻¹) at -78°C is added a solution of 60 mmol of methyl pyruvate in 120 ml of THF/HMPA (9:1) over a 1 h period. After additional 15 min at -78°C, a solution of 20 mmol of BOC-L-cyclohexylalaninal <u>8</u> in toluene (0.88 mol⁻¹) is added. The reaction mixture is warmed up to 0°C overnight and is quenched by the addition of 0.67 mol⁻¹ aqueous tartaric acid. The aqueous layer is extracted several times with diethyl ether, the combined organic layers are washed with brine, dried over sodium sulfate, filtered and concentrated. - Pure α -enol- γ -lactone <u>9</u> is obtained by recrystallization from CH₂Cl₂/hexane; mp 178°C, $[\alpha]_D^{25°C} = -22.4°$ (c=0.92, CH₂Cl₂). The crude α -enol- γ -lactone <u>9</u> is dissolved in ethyl acetate (0.1 mol⁻¹) and is hydrogenated (H₂/1 atm) overnight in the presence of 5 g of 10% Pd/C. The reaction mixture is filtered over celite and concentrated in vacuo. After chromatography (MPLC, hexane/ethyl acetate (1:1)), the α -hydroxy- γ -lactone <u>11</u> is obtained in diastereomerically pure form (> 99%, 360 MHz ¹HNMR); mp 143-144°C, $[\alpha]_D^{25°C} = -2.25°$ (c=0.4, CH₂Cl₂). The application of the new lactone <u>11</u> for the synthesis of dipeptide isosteres¹⁴ e.g. <u>13</u> and 15 and potent renin inhibitors¹⁵ <u>14</u> and <u>16</u> is shown in scheme 4.



SCHEME 4 (a) CH₂=CH-CH₂Br, Ag₂O, Et₂O; (b) n-BuNH₂, R.T.; (c) TFA, CH₂Cl₂ (1:2), R.T.; (d) Boc-Phe-Nie-OH, HOBT, EDCI,

THF/DMF (1:1), 0°C-R.T.; (e) MsCl, Pyr., R.T.; (f) MeCOONa, HMPT, THF; (g) K2CO3, MeOH, R.T.

REFERENCES

- 1. M.W. Holladay, F.G. Salituro and D.H. Rich, J. Med. Chem. 30, 374 (1987).
- a) B.E. Evans, K.E. Rittle, C.F. Homnick, J. Org. Chem. <u>50</u>, <u>4615</u> (1985);
 b) S. Thaisrivongs, J.P. Springer, J. Hirshfield and D.F. Veber, J. Med. Chem. <u>30</u>, <u>976</u> (1987).
- For recent reviews see: a) J. Boger, TIPS 8, 370 (1987); b) T. Kokubu and K. Hiwada, Drugs of Today 23, 101 (1987).
- 4. M.T. Reetz, Angew. Chem., Int. Ed. Engl. <u>23</u>, 556 (1984) and references cited therein.
- 5. H.H. Wassermann and J.L. Ives, J. Org. Chem. 43, 3238 (1978).
- 6. H. Schinz and M. Hinder, Helv. Chim. Acta 30, 1349 (1947).
- 7. C.G. Wermuth, Bull. Soc. Chim. Fr. 1966, 1435.
- 8. a) R.R. Schmidt and R. Betz, Angew. Chem., Int. Ed. Engl. 23, 430 (1984);
 b) D. Lafont, M. Hoch and R.R. Schmidt, J. Carbohydr. Chem. 5, 601 (1986).
- 9. D.J. Kempf, E. de Lara, H.H. Stein, J. Cohen and J.J. Plattner, J. Med. Chem. <u>30</u>, 1978 (1987) and references cited therein.
- 10. D.H. Rich, E.T.O. Sun and E. Ulm, J. Med. Chem. 23, 27 (1980).
- 11. J.F. Dellaria and R.G. Maki, Tetrahedron Lett. 27, 2337 (1986).
- 12. M. Cherest, H. Felkin and N. Prudent, Tetrahedron Lett. 9, 2199 (1968).
- For a similar discussion see: S. Thaisrivongs, D.T. Pals, W.M. Kati, S.R. Turner, L.M. Thomasco and W. Watt, J. Med. Chem. <u>29</u>, 2080 (1986).
- 14. Satisfactory combustion analyses and spectral data (NMR, MS) were obtained for all new compounds reported herein.
- 15. IC₅₀-values in scheme 4 are related to human renin.

(Received in Germany 15 April 1988)